MedTech & Diagnostics
Inogen Executive Compensation (FY25)
INGN · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 11, 2026
157 figures on this page: 155 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Kevin R.M. Smith, Chief Executive Officer, President and Director, received $2,613,804 in total compensation for fiscal 2025, and the company reported a chief executive pay ratio of 35:1 for fiscal 2025, against median employee compensation of $74,060. The say-on-pay proposal drew 94.8% of votes cast including abstentions in favor at the meeting held June 5, 2026 for fiscal 2025. Companies named in the disclosed peer group include Alphatec Holdings, Inc., AngioDynamics, Inc., Artivion, Inc., AtriCure, Inc. and Axogen, Inc., among others. For fiscal 2025, the company reported 5 named executive officers.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kevin Smith: $4,159,779 → $1,463,009 (64.8% lower)
Say-on-pay support: 90.8% → 94.8% (4.0 points higher)
CEO pay ratio: 53:1 → 35:1 (34.0% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Inogen's chief executive and what were they paid?
Kevin R.M. Smith, Chief Executive Officer, President and Director, received $2,613,804 in total compensation for fiscal 2025.
What was Inogen's say-on-pay result?
The say-on-pay proposal drew 94.8% of votes cast including abstentions in favor at the meeting held June 5, 2026 for fiscal 2025.
Which companies are in Inogen's peer group?
Companies named in the disclosed peer group include Alphatec Holdings, Inc., AngioDynamics, Inc., Artivion, Inc., AtriCure, Inc. and Axogen, Inc., among others.
What is Inogen's chief executive pay ratio?
The company reported a chief executive pay ratio of 35:1 for fiscal 2025, against median employee compensation of $74,060.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin R.M. Smith Chief Executive Officer and President, Director | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin R.M. Smith Chief Executive Officer and President, Director | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Bourque Former Executive Vice President, Chief Financial Officer, and Corporate Treasurer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Gregoire Ramade Executive Vice President, Chief Commercial Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin R.M. Smith Chief Executive Officer, President and Director | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Michael Bourque Former Executive Vice President, Chief Financial Officer, and Corporate Treasurer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jennifer Yi Boyer Executive Vice President, Enterprise Enablement and Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Kevin Smith Executive Vice President, General Counsel, Secretary and Business Development | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Gregoire Ramade Executive Vice President, Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Gregoire Ramade | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Gregoire Ramade | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Jennifer Yi Boyer | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Jennifer Yi Boyer | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kevin P. Smith | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Kevin P. Smith | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Bourque | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Michael Bourque | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jennifer Yi Boyer | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Kevin Smith | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Gregoire Ramade | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Bourque | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Elizabeth Mora Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Mira Sahney | ◇ | ◇ | — | — | — | — | ◇ |
Glenn Boehnlein | ◇ | ◇ | — | — | — | — | ◇ |
Mary Kay Ladone | ◇ | ◇ | — | — | — | — | ◇ |
Kevin King | ◇ | ◇ | — | — | — | — | ◇ |
Heather Rider | ◇ | ◇ | — | — | — | — | ◇ |
Thomas A. West | ◇ | — | — | — | — | — | ◇ |
Vafa Jamali and Kevin R.M. Smith served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alphatec Holdings, Inc. ATEC
- AngioDynamics, Inc. ANGO
- Artivion, Inc. AORT
- AtriCure, Inc. ATRC
- Axogen, Inc. AXGN
- Bioventus, Inc. BVS
- Inari Medical, Inc. NARI
- iRhythm Technologies, Inc. IRTC
- Kewaunee Scientific Corporation KEQU
- LeMaitre Vascular, Inc. LMAT
- Nevro Corporation NVRO
- OraSure Technologies, Inc. OSUR
- STAAR Surgical Company STAA
- Tactile Systems Technology, Inc. TCMD
- TransMedics Group, Inc. TMDX
- Treace Medical Concepts, Inc. TMCI
- ZimVie, Inc. ZIMV
- Zynex, Inc. ZYXI
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 5, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 14, 2025 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Inogen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Inogen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
157 figures on this page: 155 cited to the filing that reported them, 2 calculated from figures it prints.
155 cited to the filing
2 calculated from the filing
Documents cited
- 0001294133-26-000021Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001294133-26-0000092025 Summary Compensation Table · CEO Pay Ratio Disclosure · Compensation Table · Director Compensation · and 2 more sections
- 0000950170-25-074437Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-25-045737Compensation Table
- 0000950170-24-045541Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Inogen executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/INGN (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Inogen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Inogen discloses
The companies named in INGN's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}